Madrigal Pharmaceuticals (MDGL) Change in Acquisitions & Divestments (2011 - 2026)

Madrigal Pharmaceuticals (MDGL) has reported Change in Acquisitions & Divestments for 16 consecutive years, with $187.3 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Change in Acquisitions & Divestments fell 31.49% year-over-year to $187.3 million; the TTM figure through Jun 2026 stood at $1.1 billion (down 2.63% YoY), while the FY2025 annual figure was $1.1 billion, up 25.49% from the prior year.
• Change in Acquisitions & Divestments declined to $187.3 million in Q2 2026 per MDGL's latest filing, from $353.9 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $353.9 million in Q1 2026 and bottomed at $12.0 million in Q1 2023.
• Historically, Change in Acquisitions & Divestments has averaged $176.2 million across 5 years, with a median of $173.2 million in 2024.
• Annual changes were most pronounced in 2023 — Change in Acquisitions & Divestments plunged 87.18% — and 2024, when it jumped 1422.61%.
• Madrigal Pharmaceuticals' Change in Acquisitions & Divestments stood at $79.2 million in 2022, then jumped by 43.69% to $113.8 million in 2023, then jumped by 165.75% to $302.4 million in 2024, then decreased by 20.59% to $240.1 million in 2025, then declined by 22.01% to $187.3 million in 2026.
• Business Quant data shows MDGL's Change in Acquisitions & Divestments at $187.3 million in Q2 2026, $353.9 million in Q1 2026, and $240.1 million in Q4 2025.